Patents by Inventor Paul Edward Stephens

Paul Edward Stephens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11352414
    Abstract: The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: June 7, 2022
    Inventors: Farnaz Fallah-Arani, Robert Anthony Griffin, David Paul Humphreys, Shirley Jane Peters, Bryan John Smith, Paul Edward Stephens
  • Patent number: 10479824
    Abstract: The present invention relates to single chain polypeptides comprising one or more immunoglobulin Fc domains. In particular the present invention relates to single-chain Fc polypeptides in which at least one functional Fc domain is formed within the polypeptide chain.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: November 19, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Alastair David Griffiths Lawson, Paul Edward Stephens
  • Publication number: 20190031752
    Abstract: This invention provides a method for obtaining a recombinant antibody with a desired function, comprising: (a) providing a population of anti-body-forming cells suspected of containing at least one cell capable of producing an antibody exhibiting the desired function; (b) generating one or more transcriptionally active recombinant linear polynucleotides from the antibody-forming cells obtained in step (a) wherein each transcriptionally active recombinant linear polynucleotide comprises a polynucleotide sequence encoding a variable domain of an antibody produced by an antibody-forming cell obtained in step (a) and one or more transcription regulatory elements; (c) expressing a recombinant antibody using one or more of the transcriptionally active recombinant linear polynucleotides generated in step (b); (d) screening the recombinant antibody produced by step (c) for the desired function; and (e) optionally repeating steps (b), (c) and (d) to identify a recombinant antibody exhibiting the desired function.
    Type: Application
    Filed: February 16, 2018
    Publication date: January 31, 2019
    Inventors: Paul Edward Stephens, Michael John Wright
  • Patent number: 9476081
    Abstract: The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: October 25, 2016
    Assignee: UCB Biopharma SPRL
    Inventors: Katharine Lacy Cain, Shirley Jane Peters, Paul Edward Stephens
  • Publication number: 20150025128
    Abstract: The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell.
    Type: Application
    Filed: August 5, 2014
    Publication date: January 22, 2015
    Inventors: Katharine Lacy Cain, Shirley Jane Peters, Paul Edward Stephens
  • Patent number: 8828719
    Abstract: The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell.
    Type: Grant
    Filed: February 10, 2010
    Date of Patent: September 9, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: Katharine Lacy Cain, Shirley Jane Peters, Paul Edward Stephens
  • Publication number: 20120094297
    Abstract: The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell.
    Type: Application
    Filed: February 10, 2010
    Publication date: April 19, 2012
    Applicant: UCB PHARMA S.A.
    Inventors: Katharine Lacy Cain, Shirley Jane Peters, Paul Edward Stephens
  • Publication number: 20110313138
    Abstract: This invention provides a method for obtaining a recombinant antibody with a desired function, comprising: (a) providing a population of antibody-forming cells suspected of containing at least one cell capable of producing an antibody exhibiting the desired function; (b) generating one or more transcriptionally active recombinant linear polynucleotides from the antibody forming cells obtained in step (a) wherein each transcriptionally active recombinant linear polynucleotide comprises a polynucleotide sequence encoding a variable domain of an antibody produced by an antibody-forming cell obtained in step (a) and one or more transcription regulatory elements; (c) expressing a recombinant antibody using one or more of the transcriptionally active recombinant linear polynucleotides generated in step (b); (d) screening the recombinant antibody produced by step (c) for the desired function; and (e) optionally repeating steps (b), (c) and (d) to identify a recombinant antibody exhibiting the desired function.
    Type: Application
    Filed: February 25, 2010
    Publication date: December 22, 2011
    Applicant: UCB PHARMA, S.A.
    Inventors: Paul Edward Stephens, Michael John Wright
  • Publication number: 20090304696
    Abstract: The present invention relates to single chain polypeptides comprising one or more immunoglobulin Fc domains. In particular the present invention relates to single-chain Fc polypeptides in which at least one functional Fc domain is formed within the polypeptide chain.
    Type: Application
    Filed: July 24, 2007
    Publication date: December 10, 2009
    Applicant: UCB PHARMA S.A.
    Inventors: Alastair David Griffiths Lawson, Paul Edward Stephens